Tyrosine Kinase Inhibitors: Global Market Outlook

The Janus Kinase (JAK) Inhibitors Global Market Report 2023, provides comprehensive information on the janus kinase (JAK) inhibitors market across 60+ geographies in the seven regions – Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa for the 27 major global industries. The report covers a ten year historic period – 2010-2021, and a ten year forecast period – 2023-2032.

Learn More On The Janus Kinase (JAK) Inhibitors Market’s Growth:

https://www.thebusinessresearchcompany.com/report/janus-kinase-jak-inhibitors-global-market-report

As per The Business Research Company’s Janus Kinase (JAK) Inhibitors Global Market Report 2023, the global Janus Kinase (JAK) inhibitors market is expected to grow from $14.61 billion in 2022 to $17.29 billion in 2023 at a compound annual growth rate (CAGR) of 18.3%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The Janus Kinase (JAK) inhibitors market is expected to reach $33.38 billion in 2027 at a CAGR of 17.9%.

Get A Free Sample Of The Report (Includes Graphs And Tables):
https://www.thebusinessresearchcompany.com/sample_request?id=12524&type=smp

Product innovation is a key trend gaining popularity in the Janus kinase (JAK) inhibitors market. Major companies operating in the Janus kinase (JAK) inhibitors market are focused on innovating technologically advanced solutions to sustain their position in the market. For instance, in May 2022, Eli Lilly and Company, a US-based pharmaceutical company, and Incyte, a Switzerland-based biopharmaceutical company, announced the approval of OLUMIANT (baricitinib) by the U.S. Food and Drug Administration (FDA). It is the first and only JAK inhibitor FDA-approved for treating COVID-19 in some hospitalized individuals who need varying levels of oxygen assistance. OLUMIANT is approved for treating adult hospital patients with extracorporeal membrane oxygenation (ECMO), non-invasive or invasive mechanical breathing, or COVID-19 disease 2019 (COVID-19).

The janus kinase (JAK) inhibitors market is segmented:

1) By Inhibitors Type: Ruxolitinib, Tofacitinib, Oclacitinib, Baricitinib, Peficitinib, Other Inhibitor Types

2) By Mode Of Administration: Injectable, Oral, Other Modes Of Administration

3) By Distribution Channel: Hospital pharmacies, Retail pharmacies, Online pharmacies

4) By Application: Autoimmune Disorders, Oncology, Inflammatory Disorders, Metabolic Disorders

North America was the largest region in the janus kinase (JAK) inhibitors market in 2022.

The table of contents in TBRC’s janus kinase (JAK) inhibitors market report includes:

1. Executive Summary
2. Janus Kinase (JAK) Inhibitors Market Characteristics
3. Janus Kinase (JAK) Inhibitors Market Trends And Strategies
4. Janus Kinase (JAK) Inhibitors Market – Macro Economic Scenario
5. Global Janus Kinase (JAK) Inhibitors Market Size and Growth

.

.

.

32. Global Janus Kinase (JAK) Inhibitors Market Competitive Benchmarking
33. Global Janus Kinase (JAK) Inhibitors Market Competitive Dashboard
34. Key Mergers And Acquisitions In The Janus Kinase (JAK) Inhibitors Market
35. Janus Kinase (JAK) Inhibitors Market Future Outlook and Potential Analysis
36. Appendix

Learn About Us:

The Business Research Company is a market intelligence firm that pioneers in market, company, and consumer research. TBRC’s specialist consultants are located globally and are experts in a wide range of industries that include healthcare, manufacturing, financial services, chemicals, and technology. The firm has offices located in the UK, the US, and India, along with a network of proficient researchers in 28 countries. Through the report businesses can gain a thorough understanding of the market’s size, growth rate, major drivers and leading players.

Contact Us:
The Business Research Company
Europe: +44 207 1930 708

Asia: +91 88972 63534

Americas: +1 315 623 0293

Email: info@tbrc.info

 

Follow Us On:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

Twitter: https://twitter.com/tbrc_info

Facebook: https://www.facebook.com/TheBusinessResearchCompany

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Blog: https://blog.tbrc.info/

Healthcare Blog: https://healthcareresearchreports.com/

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model